Comparison · NCT03023046-c2696404
Ph+ Subjects vs Ph- Subjects: Number of Participants With Morphological Complete Response Rate
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ph+ Subjects vs Ph- Subjects: Number of Participants With Morphological Complete Response Rate. Trial comparisons, record NCT03023046-c2696404. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03023046-c2696404
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.964 | 0.823 | 0.994 | wilson | |
| Risk in group 2 | 0.8 | 0.609 | 0.911 | wilson | |
| Risk difference, group 1 minus group 2 | 0.164 | -0.0157 | 0.358 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.21 | 0.978 | 1.48 | log | |
| Odds ratio, group 1 over group 2 | 6.75 | 0.731 | 62.4 | log | |
| Number needed to treat, for one more participant with the outcome on Ph+ Subjects than on Ph- Subjects | 6.09 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ph+ Subjects | Subjects who have Philadelphia chromosome mutation | 27 | 28 | OG000 |
| Group 2 | Ph- Subjects | Subjects who do not have Philadelphia chromosome mutation | 20 | 25 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Morphological Complete Response Rate
- Description
- Morphological complete remission (CR) was determined by bone marrow aspirate morphology and defined as \<5% blasts by morphology, absolute neutrophil count \>1000/uL, and platelet count \>100,000/uL.
- Time frame
- Within 4 cycles of study therapy
- Population
Source ClinicalTrials.gov
Trial
- Title
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT number
- NCT03023046
- Phases
- PHASE2
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- Cyclophosphamide, Dasatinib, Doxorubicin, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate
- Lead sponsor
- University of Washington
- Results first posted
- 2022-07-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03023046?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03023046-c2696404